Levetiracetam Oral Solution is designed to treat seizures in patients over a month old. It was found to contain the bacteria Bacillus subtilis.
Though the bacteria has a low chance of causing infection, it has been shown to cause serious systemic infections. The likelihood of infection depends on the degree of contamination, dose and duration of the treatment and the patient’s underlying conditions. Immunocompromised patients have a higher risk of severe infections.
Lannett said it has not received any reports of adverse events related to this recall.
The affected drugs were distributed nationwide to wholesalers and distributors. Consumers should contact their pharmacies to return the product
Read the full news release here.
More articles on pharmacy:
Novartis plans giveaway of world’s most expensive drug
Albertsons launches 1- to 2-hour prescription deliveries
Smart Pharmacy lays off most of workforce
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.